HCP-patient discussion guide
How can I discuss SPRAVATO® with my patients?
If you would like to talk through the information in the patient and carer booklets during a consultation, you can download the HCP-patient discussion guide.
The guide provides key points for discussion and probing questions to facilitate conversations between you and your patients.
.png?width=265&height=218&format=webp&quality=60)
Now including guidance for patients experiencing a psychiatric emergency due to major depressive disorder (MDD-PE)
Learn more about what makes SPRAVATO® a breakthrough therapy*[1][2]
Connect with peers who have SPRAVATO® prescribing experience.
Access live and recorded meetings
* Following the approval of the SSRI fluoxetine in 1987, approved treatments have continued to primarily target the monoaminergic system.[3][4] In contrast, SPRAVATO® is an antagonist of the NMDA glutamate receptor.[5]
Abbreviations
HCP, healthcare professional; MDD-PE, psychiatric emergency due to major depressive disorder; NMDA, N-methyl-D-aspartate; SSRI, selective serotonin reuptake inhibitor.
[Insert local AE reporting text as required]
[Insert link to PI]
[Request information from the Janssen Medical Information team]
[Contact your Janssen Account Manager or Medical Scientific Liaison Manager]
